<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01349816</url>
  </required_header>
  <id_info>
    <org_study_id>PT003004</org_study_id>
    <nct_id>NCT01349816</nct_id>
  </id_info>
  <brief_title>PT003 MDI Dose Confirmation Study</brief_title>
  <official_title>A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its
      individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic
      obstructive pulmonary disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 AUC0-12</measure>
    <time_frame>Day 7</time_frame>
    <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 relative to baseline following chronic dosing (1 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Peak change from baseline in FEV1 through 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Action</measure>
    <time_frame>Day 1</time_frame>
    <description>At least 10% improvement in mean FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>At Least 12% Improvement in FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of subjects achieving &gt;=12% improvement in FEV1 relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change in IC</measure>
    <time_frame>Day 1</time_frame>
    <description>Mean inspiratory capacity (IC) of 1 and 2 hours post-dose minus baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-dose FEV1</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in morning pre-dose FEV1 (average of 60- and 30-minute pre-dose values on Day 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Through 6 Hours</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak change from baseline in FEV1 through 6 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in IC</measure>
    <time_frame>Day 7</time_frame>
    <description>Peak change from baseline in inspiratory capacity (IC) (mean of 1 and 2 hours post-dose minus baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Evening Trough FEV1</measure>
    <time_frame>Day 7</time_frame>
    <description>Change from baseline in mean evening 12-hour post-dose trough FEV1</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT003 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT003 (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT003 MDI Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT001 MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PT005 MDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT003</intervention_name>
    <description>PT003 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>PT003 (Dose 1)</arm_group_label>
    <arm_group_label>PT003 (Dose 2)</arm_group_label>
    <arm_group_label>PT003 (Dose 3)</arm_group_label>
    <arm_group_label>PT003 (Dose 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT001</intervention_name>
    <description>PT001 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>PT001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT005</intervention_name>
    <description>PT005 MDI administered as two puffs BID for 7 days</description>
    <arm_group_label>PT005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of &lt; or = 0.70

          -  A measured post- bronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2011</study_first_posted>
  <results_first_submitted>May 21, 2016</results_first_submitted>
  <results_first_submitted_qc>April 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2017</results_first_posted>
  <disposition_first_submitted>May 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 24, 2013</disposition_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Conducted at 14 US sites from July-November 2011. Entire study period of study participation was a maximum of 9 weeks.</recruitment_details>
      <pre_assignment_details>Study was a chronic dosing study; each participant received 2 of 6 possible treatments; each treatment period was separated by a washout period of at least 7 days. Patients were randomized into one of 30 treatment sequences. Each sequence included exactly 2 of the 6 treatment groups for this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Overall Study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GP MDI 36 µg</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 36/7.2 µg</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 36/9.6 µg</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 18/9.6 µg</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI 9/9.6 µg</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FF MDI 9.6 µg</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-specified criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population included all randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>All patients randomized and treated</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="185"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="9.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 AUC0-12</title>
        <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 relative to baseline following chronic dosing (1 week).</description>
        <time_frame>Day 7</time_frame>
        <population>Modified Intent to Treat (MITT) Population is made of participants who completed both treatment periods and had Pre-dose Day 1 data for both and no protocol deviations believed to have a potential impact on efficacy results. Subjects must have had data for the given endpoint to be included.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC0-12</title>
          <description>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-12 relative to baseline following chronic dosing (1 week).</description>
          <population>Modified Intent to Treat (MITT) Population is made of participants who completed both treatment periods and had Pre-dose Day 1 data for both and no protocol deviations believed to have a potential impact on efficacy results. Subjects must have had data for the given endpoint to be included.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.467" lower_limit="1.424" upper_limit="1.511"/>
                    <measurement group_id="O2" value="1.462" lower_limit="1.418" upper_limit="1.508"/>
                    <measurement group_id="O3" value="1.493" lower_limit="1.448" upper_limit="1.539"/>
                    <measurement group_id="O4" value="1.499" lower_limit="1.455" upper_limit="1.544"/>
                    <measurement group_id="O5" value="1.399" lower_limit="1.358" upper_limit="1.441"/>
                    <measurement group_id="O6" value="1.465" lower_limit="1.423" upper_limit="1.509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1</title>
        <description>Peak change from baseline in FEV1 through 2 hours</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1</title>
          <description>Peak change from baseline in FEV1 through 2 hours</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.312" lower_limit="0.265" upper_limit="0.359"/>
                    <measurement group_id="O2" value="0.308" lower_limit="0.259" upper_limit="0.358"/>
                    <measurement group_id="O3" value="0.344" lower_limit="0.295" upper_limit="0.393"/>
                    <measurement group_id="O4" value="0.350" lower_limit="0.304" upper_limit="0.397"/>
                    <measurement group_id="O5" value="0.248" lower_limit="0.201" upper_limit="0.294"/>
                    <measurement group_id="O6" value="0.307" lower_limit="0.260" upper_limit="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Action</title>
        <description>At least 10% improvement in mean FEV1</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Action</title>
          <description>At least 10% improvement in mean FEV1</description>
          <population>MITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="0.265" upper_limit="0.359"/>
                    <measurement group_id="O2" value="21" lower_limit="0.259" upper_limit="0.358"/>
                    <measurement group_id="O3" value="20" lower_limit="0.295" upper_limit="0.393"/>
                    <measurement group_id="O4" value="30" lower_limit="0.304" upper_limit="0.397"/>
                    <measurement group_id="O5" value="15" lower_limit="0.201" upper_limit="0.294"/>
                    <measurement group_id="O6" value="24" lower_limit="0.260" upper_limit="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No onset within 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>At Least 12% Improvement in FEV1</title>
        <description>Proportion of subjects achieving &gt;=12% improvement in FEV1 relative to baseline</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>At Least 12% Improvement in FEV1</title>
          <description>Proportion of subjects achieving &gt;=12% improvement in FEV1 relative to baseline</description>
          <population>MITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="0.265" upper_limit="0.359"/>
                    <measurement group_id="O2" value="17" lower_limit="0.259" upper_limit="0.358"/>
                    <measurement group_id="O3" value="18" lower_limit="0.295" upper_limit="0.393"/>
                    <measurement group_id="O4" value="27" lower_limit="0.304" upper_limit="0.397"/>
                    <measurement group_id="O5" value="13" lower_limit="0.201" upper_limit="0.294"/>
                    <measurement group_id="O6" value="22" lower_limit="0.260" upper_limit="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No onset within 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change in IC</title>
        <description>Mean inspiratory capacity (IC) of 1 and 2 hours post-dose minus baseline</description>
        <time_frame>Day 1</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change in IC</title>
          <description>Mean inspiratory capacity (IC) of 1 and 2 hours post-dose minus baseline</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.323" lower_limit="0.249" upper_limit="0.397"/>
                    <measurement group_id="O2" value="0.242" lower_limit="0.165" upper_limit="0.319"/>
                    <measurement group_id="O3" value="0.339" lower_limit="0.264" upper_limit="0.415"/>
                    <measurement group_id="O4" value="0.326" lower_limit="0.254" upper_limit="0.398"/>
                    <measurement group_id="O5" value="0.228" lower_limit="0.156" upper_limit="0.300"/>
                    <measurement group_id="O6" value="0.316" lower_limit="0.244" upper_limit="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-dose FEV1</title>
        <description>Change from baseline in morning pre-dose FEV1 (average of 60- and 30-minute pre-dose values on Day 7)</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-dose FEV1</title>
          <description>Change from baseline in morning pre-dose FEV1 (average of 60- and 30-minute pre-dose values on Day 7)</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.152" lower_limit="0.105" upper_limit="0.199"/>
                    <measurement group_id="O2" value="0.110" lower_limit="0.061" upper_limit="0.159"/>
                    <measurement group_id="O3" value="0.122" lower_limit="0.073" upper_limit="0.170"/>
                    <measurement group_id="O4" value="0.131" lower_limit="0.085" upper_limit="0.177"/>
                    <measurement group_id="O5" value="0.100" lower_limit="0.053" upper_limit="0.146"/>
                    <measurement group_id="O6" value="0.103" lower_limit="0.057" upper_limit="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Through 6 Hours</title>
        <description>Peak change from baseline in FEV1 through 6 hours</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Through 6 Hours</title>
          <description>Peak change from baseline in FEV1 through 6 hours</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.362" lower_limit="0.309" upper_limit="0.414"/>
                    <measurement group_id="O2" value="0.356" lower_limit="0.300" upper_limit="0.412"/>
                    <measurement group_id="O3" value="0.388" lower_limit="0.334" upper_limit="0.443"/>
                    <measurement group_id="O4" value="0.415" lower_limit="0.363" upper_limit="0.467"/>
                    <measurement group_id="O5" value="0.283" lower_limit="0.231" upper_limit="0.336"/>
                    <measurement group_id="O6" value="0.355" lower_limit="0.302" upper_limit="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in IC</title>
        <description>Peak change from baseline in inspiratory capacity (IC) (mean of 1 and 2 hours post-dose minus baseline)</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in IC</title>
          <description>Peak change from baseline in inspiratory capacity (IC) (mean of 1 and 2 hours post-dose minus baseline)</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="51"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.333" lower_limit="0.246" upper_limit="0.420"/>
                    <measurement group_id="O2" value="0.267" lower_limit="0.177" upper_limit="0.357"/>
                    <measurement group_id="O3" value="0.340" lower_limit="0.252" upper_limit="0.429"/>
                    <measurement group_id="O4" value="0.351" lower_limit="0.267" upper_limit="0.436"/>
                    <measurement group_id="O5" value="0.228" lower_limit="0.143" upper_limit="0.313"/>
                    <measurement group_id="O6" value="0.354" lower_limit="0.269" upper_limit="0.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Evening Trough FEV1</title>
        <description>Change from baseline in mean evening 12-hour post-dose trough FEV1</description>
        <time_frame>Day 7</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI 36/7.2 µg</title>
            <description>GFF MDI 36/7.2 µg BID</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI 36/9.6 µg</title>
            <description>GFF MDI 36/9.6 µg BID</description>
          </group>
          <group group_id="O3">
            <title>GFF MDI 18/9.6 µg</title>
            <description>GFF MDI 18/9.6 µg BID</description>
          </group>
          <group group_id="O4">
            <title>GFF MDI 9/9.6 µg</title>
            <description>GFF MDI 9/9.6 µg BID</description>
          </group>
          <group group_id="O5">
            <title>GP MDI 36 µg</title>
            <description>GP MDI 36 µg BID</description>
          </group>
          <group group_id="O6">
            <title>FF MDI 9.6 µg</title>
            <description>FF MDI 9.6 µg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Evening Trough FEV1</title>
          <description>Change from baseline in mean evening 12-hour post-dose trough FEV1</description>
          <population>MITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" lower_limit="0.032" upper_limit="0.129"/>
                    <measurement group_id="O2" value="0.073" lower_limit="0.023" upper_limit="0.123"/>
                    <measurement group_id="O3" value="0.105" lower_limit="0.055" upper_limit="0.154"/>
                    <measurement group_id="O4" value="0.112" lower_limit="0.064" upper_limit="0.159"/>
                    <measurement group_id="O5" value="0.081" lower_limit="0.033" upper_limit="0.129"/>
                    <measurement group_id="O6" value="0.120" lower_limit="0.073" upper_limit="0.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed consent up to the follow-up (Final) visit or premature discontinuation visit.</time_frame>
      <desc>Safety population included all participants who received at least one dose of study drug, with safety data available. Serious adverse events were collected from the time the subject signed consent up to 14 days following the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>GFF MDI 36/7.2 µg</title>
          <description>GFF MDI 36/7.2 µg BID</description>
        </group>
        <group group_id="E2">
          <title>GFF MDI 36/9.6 µg</title>
          <description>GFF MDI 36/9.6 µg BID</description>
        </group>
        <group group_id="E3">
          <title>GFF MDI 18/9.6 µg</title>
          <description>GFF MDI 18/9.6 µg BID</description>
        </group>
        <group group_id="E4">
          <title>GFF MDI 9/9.6 µg</title>
          <description>GFF MDI 9/9.6 µg BID</description>
        </group>
        <group group_id="E5">
          <title>GP MDI 36 µg</title>
          <description>GP MDI 36 µg BID</description>
        </group>
        <group group_id="E6">
          <title>FF MDI 9.6 µg</title>
          <description>FF MDI 9.6 µg BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent its opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc</organization>
      <phone>650-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

